CRL Charles River Laboratories International Inc

Price (delayed)

$278.27

Market cap

$13.85B

P/E Ratio

37.86

Dividend/share

N/A

EPS

$7.35

Enterprise value

$15.76B

Sector: Healthcare
Industry: Diagnostics & Research

Charles River Laboratories, Inc., is an American corporation specializing in a variety of preclinical and clinical laboratory services for the pharmaceutical, medical device and biotechnology industries. It also supplies assorted ...

Highlights

The net income has increased by 45% year-on-year and by 21% since the previous quarter
The EPS rose by 42% YoY and by 20% QoQ
The price to earnings (P/E) is 23% higher than the 5-year quarterly average of 30.8 and 21% higher than the last 4 quarters average of 31.4
Charles River Laboratories International's debt has increased by 7% YoY

Key stats

What are the main financial stats of CRL
Market
Shares outstanding
49.78M
Market cap
$13.85B
Enterprise value
$15.76B
Valuations
Price to earnings (P/E)
37.86
Price to book (P/B)
6.55
Price to sales (P/S)
4.72
EV/EBIT
29.59
EV/EBITDA
20.53
EV/Sales
5.39
Earnings
Revenue
$2.92B
EBIT
$532.55M
EBITDA
$767.47M
Free cash flow
$380.02M
Per share
EPS
$7.35
Free cash flow per share
$7.67
Book value per share
$42.51
Revenue per share
$59.01
TBVPS
$58.41
Balance sheet
Total assets
$5.49B
Total liabilities
$3.35B
Debt
$2.14B
Equity
$2.11B
Working capital
$361.38M
Liquidity
Debt to equity
1.01
Current ratio
1.43
Quick ratio
1.01
Net debt/EBITDA
2.48
Margins
EBITDA margin
26.2%
Gross margin
36.7%
Net margin
12.5%
Operating margin
14.8%
Efficiency
Return on assets
6.9%
Return on equity
19.6%
Return on invested capital
13.5%
Return on capital employed
11.4%
Return on sales
18.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRL stock price

How has the Charles River Laboratories International stock price performed over time
Intraday
-3.2%
1 week
-3.45%
1 month
3.89%
1 year
72.29%
YTD
11.37%
QTD
11.37%

Financial performance

How have Charles River Laboratories International's revenue and profit performed over time
Revenue
$2.92B
Gross profit
$1.07B
Operating income
$432.73M
Net income
$364.3M
Gross margin
36.7%
Net margin
12.5%
The net income has increased by 45% year-on-year and by 21% since the previous quarter
Charles River Laboratories International's net margin has increased by 30% YoY and by 17% QoQ
CRL's operating income is up by 23% YoY and by 4.9% QoQ
Charles River Laboratories International's gross profit has increased by 12% YoY and by 3.6% QoQ

Growth

What is Charles River Laboratories International's growth rate over time

Valuation

What is Charles River Laboratories International stock price valuation
P/E
37.86
P/B
6.55
P/S
4.72
EV/EBIT
29.59
EV/EBITDA
20.53
EV/Sales
5.39
The EPS rose by 42% YoY and by 20% QoQ
The price to earnings (P/E) is 23% higher than the 5-year quarterly average of 30.8 and 21% higher than the last 4 quarters average of 31.4
The price to book (P/B) is 39% higher than the 5-year quarterly average of 4.7 and 31% higher than the last 4 quarters average of 5.0
The equity is up by 29% year-on-year and by 11% since the previous quarter
The P/S is 69% higher than the 5-year quarterly average of 2.8 and 39% higher than the last 4 quarters average of 3.4
CRL's revenue is up by 12% year-on-year and by 3.5% since the previous quarter

Efficiency

How efficient is Charles River Laboratories International business performance
The ROS rose by 32% YoY and by 12% QoQ
The company's return on invested capital rose by 29% YoY and by 13% QoQ
The company's return on assets rose by 21% YoY and by 17% QoQ
The ROE has grown by 17% YoY and by 13% from the previous quarter

Dividends

What is CRL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRL.

Financial health

How did Charles River Laboratories International financials performed over time
The company's total assets is 64% higher than its total liabilities
The company's total assets rose by 17% YoY and by 5% QoQ
The quick ratio has declined by 4.7% year-on-year and by 2.9% since the previous quarter
The equity is up by 29% year-on-year and by 11% since the previous quarter
Charles River Laboratories International's debt to equity has decreased by 18% YoY and by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.